AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses

AnGes’ COVID-19 DNA vaccine candidate has fallen shy of demonstrating its expected results in its PI/II and PII/III studies, according to the results from a series clinical studies, the company said on November 5. In its studies launched since 2020,...read more